Reuters logo
BRIEF-Sage Therapeutics announces Brexanolone achieves primary endpoints
November 9, 2017 / 11:16 AM / a month ago

BRIEF-Sage Therapeutics announces Brexanolone achieves primary endpoints

Nov 9 (Reuters) - Sage Therapeutics Inc:

* Announces Brexanolone achieves primary endpoints in both phase 3 clinical trials in postpartum depression

* Statistically significant mean reduction in HAM-D score compared to placebo at 60 hours demonstrated in both trials​

* Brexanolone was generally well tolerated and showed a similar safety profile as seen in earlier studies​

* Brexanolone achieved primary endpoint in both trials​

* In each trial, 1 patient experienced serious adverse event; neither required hospitalization, 1 deemed not to be study-drug related​

* Sage plans to file a New Drug Application (NDA) with U.S. Food and Drug Administration in 2018 for Brexanolone​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below